Anifrolumab Asian PhIII efficacy study for Systemic Lupus Erythematosus (SLE)

Trial Identifier: D3468C00003
Sponsor: AstraZeneca
Start Date: September 2021
Primary Completion Date: April 2025
Study Completion Date: June 2025
Condition: Lupus

Available Languages

For questions about your Trial Results Summary, please see Sponsor contact section within your Trial Results Summary.

No documents have been posted yet.

Trial Locations

Country Location
CN Baoding, CN, 071000
CN Baotou, CN, 014010
CN Beijing, CN, 100144
CN Beijing, CN, 100191
CN Beijing, CN, 100730
CN Beijing, CN, 100034
CN Beijing, CN, 100029
CN Bengbu, CN, 233004
CN Binzhou, CN, 256603
CN Changchun, CN
CN Changsha, CN, 410008
CN Chuangchun, CN, 130012
CN Guangzhou, CN, 510080
CN Guangzhou, CN, 510260
CN Guilin, CN, 541001
CN Hangzhou, CN, 310006
CN Hengyang, CN, 421001
CN Jieyang, CN, 522000
CN Jinan, CN, 250012
CN JINING, CN, 272011
CN Kunming, CN, 650032
CN lanzhou, CN, 730000
CN Linyi, CN, 276003
CN Luoyang, CN, 471003
CN Nan Chong, CN, 637000
CN Nanchang, CN, 330006
CN Nanjing, CN, 210008
CN Nanyang, CN, 473005
CN Shanghai, CN, 200025
CN Shengyang, CN, 110004
CN Shenyang, CN, 110001
CN Shenzhen, CN, 518020
CN Shijiazhuang, CN, 050001
CN suzhou, CN, 215006
CN Tianjin, CN, 300050
CN Urumqi, CN, 831118
CN Wenzhou, CN, 325000
CN Wuhan, CN, 430022
CN Wuhan, CN, 430030
CN Wuxi, CN, 214002
CN Xiamen, CN, 361003
CN Xinxiang, CN, 453002
CN Yinchuan, CN, 750004
CN Zaozhuang City, CN, 277102
CN Zhengzhou, CN, 450052
HK Hong Kong, HK
HK Hong Kong, HK, 00000
KR Gwangju, KR, 501-757
KR Seoul, KR, 6591
KR Seoul, KR, 04763
KR Suwon-si, KR, 16499
PH Davao City, PH, PH-8000
PH Iloilo, PH, 5000
PH Iloilo City, PH, 5000
PH Lipa City, PH, 4217
PH Manila, PH, 1000
PH Quezon City, PH, 1112
TW Kaohsiung, TW, 81362
TW New Taipei, TW, 220
TW New Taipei, TW, 23561
TW Taichung, TW, 40447
TW Taichung, TW, 40705
TW Taipei, TW, 11220
TW Taipei, TW, 114
TW Tao-Yuan, TW, 333